ERBB2 and neoplasm: Historically, ERBB2 gene amplification and protein overexpression in tumor biopsy material, as measured by in situ hybridization (ISH) or immunohistochemistry (IHC), has been used to select patients most likely to benefit from HER2-based therapeutic strategies.